Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidance released for $1 billion in tax credits

This article was originally published in The Gray Sheet

Executive Summary

Beginning June 21, qualifying companies with 250 or fewer employees may apply for the new Therapeutic Discovery Project Program tax credit, assuming their projects "show a reasonable potential" to address unmet medical needs, reduce health care costs or advance cancer research. The application period runs through July 21, 2010. HHS will evaluate applications and the IRS will issue certifications no later than Oct. 29, 2010. Individual tax credits of up to $5 million are available per qualifying firm to cover up to 50% of the cost of qualifying biomedical research in 2009 and 2010. Firms can opt for a grant instead. The Treasury Department and National Institutes of Health jointly announced the 1guidelines on May 21. Authorization for the tax credit was included in the recent health reform law

You may also be interested in...

Health Reform Delivers Cash, Credits To 3,000 Small Health Tech Firms

Nearly 3,000 U.S. health care technology companies will receive the first round of federal grant or tax credit awards under a provision of the Affordable Care Act, federal officials announced Nov. 3.

Diagnostics Firms Poised To Gain From Innovation Tax Credit Program

Diagnostics firms stand to benefit most among medical device companies from $1 billion in life sciences innovation tax credits approved earlier this year, according to AdvaMed

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts